Search Within

Ghassan Abou-Alfa

Formats
  1. Meeting Abstract (262)
  2. Journal Article (246)
  3. Review (27)
  4. Book Section (16)
  5. Editorial (8)
  6. Book Whole (4)
  7. Correspondence (4)
  8. Guidelines (4)
  9. Miscellaneous (3)
  10. Research Letter (1)
Groups
  1. Department of Medicine (575)
  2. Gastrointestinal Oncology Service (575)
  3. Solid Tumor Oncology Division (575)
  4. Center for Pancreatic Cancer Research (215)
  5. Epidemiology and Biostatistics (122)
  6. Surgery (103)

More Groups

People
  1. Eileen O'Reilly (156)
  2. James Harding (130)
  3. William Jarnagin (66)
  4. Marinela Capanu (65)
  5. Leonard Saltz (55)
  6. Imane El Dika (54)

More People

Years
  1. 2025 (20)
  2. 2024 (52)
  3. 2023 (48)
  4. 2022 (53)
  5. 2021 (46)
  6. 2020 (46)

More Years

Publications
  1. Journal of Clinical Oncology (166)
  2. Annals of Oncology (53)
  3. Gastrointestinal Cancer Research (21)
  4. Oncology Research and Treatment (18)
  5. Annals of Surgical Oncology (15)
  6. Cancer (14)

More Publications

Publishers
  1. American Society of Clinical Oncology (182)
  2. Oxford University Press (65)
  3. Springer (36)
  4. Wiley Blackwell (30)
  5. Elsevier Inc. (25)
  6. Elsevier Science, Inc. (24)

More Publishers

Results (575)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Pemigatinib for previously treated locally advanced or metastatic cholangiocarcinoma: Final results from Fight-202
    Meeting Abstract

    Vogel, A.; Sahai, V.; Hollebecque, A.; Vaccaro, G. M.; Melisi, D.; Rajabi, R. M.; Paulson, A. S.; Borad, M. J.; Gallinson, D.; Murphy, A. G.; more...
    Gut (2022)

    Fulltext@MSK | Save
  • Impact of viral aetiology in the phase III HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular carcinoma (uHCC)
    Meeting Abstract

    Chan, L. S.; Kudo, M.; Sangro, B.; Kelley, R. K.; Furuse, J.; Park, J. W.; Sunpaweravong, P.; Fasolo, A.; Yau, T.; Kawaoka, T.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • A randomised phase III study of tremelimumab (T) plus durvalumab (D) with or without lenvatinib combined with concurrent transarterial chemoembolisation (TACE) versus TACE alone in patients (pts) with locoregional hepatocellular carcinoma (HCC): EMERALD-3
    Meeting Abstract

    Abou-Alfa, G. K.; Fan, J.; Heo, J.; Arai, Y.; Erinjeri, J. P.; Kuhl, C. K.; Lencioni, R.; Ren, Z.; Zeng, A.; Evans, B.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Final results from the NIFTY trial, a phase IIb, randomized, open-label study of liposomal Irinotecan (nal-IRI) plus fluorouracil (5-FU)/leucovorin (LV) in patients (pts) with previously treated metastatic biliary tract cancer (BTC)
    Meeting Abstract

    Yoo, C.; Kim, K. P.; Kim, I.; Kang, M. J.; Cheon, J.; Kang, B. W.; Ryu, H.; Jeong, J.; Lee, J. S.; Kim, K. W.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Efficacy of derazantinib in intrahepatic cholangiocarcinoma (iCCA) patients with FGFR2 fusions, mutations or amplifications
    Meeting Abstract

    Borad, M.; Javle, M.; Shaib, W. L.; Mody, K.; Bergamo, F.; Harris, W. P.; Damjanov, N.; Macarulla, T.; Brandi, G.; Masi, G.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Neo-adjuvant FOLFIRINOX in borderline resectable and locally advanced pancreatic adenocarcinoma
    Journal Article

    Temraz, S.; Nassar, F.; Hammoud, M. S.; Mukherji, D.; O'Reilly, E. M.; Dbouk, H.; Farhat, F.; Charafeddine, M.; Faraj, W.; Khalifeh, M. J.; more...
    Asia-Pacific Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Comprehensive molecular characterization of gallbladder carcinoma and potential targets for intervention
    Journal Article

    Giraldo, N. A.; Drill, E.; Satravada, B. A.; El Dika, I.; Brannon, A. R.; Dermawan, J.; Mohanty, A.; Ozcan, K.; Chakravarty, D.; Benayed, R.; more...
    Clinical Cancer Research (2022)

    Fulltext@MSK | Save
  • Patient-reported outcomes from the phase 3 HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma
    Meeting Abstract

    Sangro, B.; Galle, P. R.; Kelley, R. K.; Charoentum, C.; De Toni, E. N.; Ostapenko, Y.; Heo, J.; Cheng, A. L.; Vogel, A.; Marcovitz, M.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Immunogenomic characterization of biliary tract cancers: Biomarker enrichment for benefit to immune checkpoint blockade
    Meeting Abstract

    Park, W.; Keane, F.; Bandlamudi, C.; Donoghue, M.; de Lara, P. T.; Harding, J. J.; Khalil, D.; McKinnell, Z.; Sterpi, M.; Cao, W.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Clinical and genomic characterization of ERBB2-altered gallbladder cancer
    Meeting Abstract

    Mondaca, S.; Schultz, N.; Roa, J. C.; Walch, H. S.; Sepulveda, S.; Harding, J. J.; Yaqubie, A.; Garcia, P.; Aguayo, G.; Nervi, B.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save